EPISODE · Jun 3, 2026 · 14 MIN
2411: Poolbeg Pharma: What US Payers Really Said
from The Vox Markets Podcast · host Vox Markets Podcast
Watch on YouTubeIndependent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.
NOW PLAYING
2411: Poolbeg Pharma: What US Payers Really Said
0:00
14:41
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of The Vox Markets Podcast?
This episode is 14 minutes long.
When was this The Vox Markets Podcast episode published?
This episode was published on June 3, 2026.
What is this episode about?
Watch on YouTubeIndependent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what...
Can I download this The Vox Markets Podcast episode?
Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!